化合物信息

Drug Groups

approved

Description

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Indication

For the treatment of ocular itching associated with allergic conjunctivitis.

Pharmacology

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Affected Organisms

Biotransformation

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

Absorption

Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.

Half Life

3 hours

Elimination

Elimination was predominantly through renal excretion.

References

External Links